Drug intelligence / Profile preview

RituxiRel

Development stage: Unknown
Lead developer: Reliance Life Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RituxiRel is a rituximab biosimilar developed and manufactured by Reliance Life Sciences. It is a chimeric murine/human monoclonal IgG1 kappa antibody that specifically targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding, RituxiRel mediates B-cell depletion through multiple mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and the induction of apoptosis. It is indicated for the treatment of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as autoimmune disorders including rheumatoid arthritis (in combination with methotrexate), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA).

Brand names: RituxiRel
Other names: rituximab

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on RituxiRel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RituxiRel.

Explore the full profile